SEC Filing Summary: BioDrain Medical, Inc. (10-Q)
Business Context and Reporting Period
Company: BioDrain Medical, Inc. (Note: Request metadata listed "Axe Compute Inc.", but the filing text identifies BioDrain Medical, Inc.)
Period: Quarterly report for the period ended September 30, 2009.
Status: Development stage company incorporated in 2002. The company develops an environmentally safe system for collecting and disposing of infectious fluids from surgical procedures (Fluid Management System or "FMS").
Regulatory Milestone: Received FDA 510(k) clearance on April 1, 2009, authorizing the marketing and sale of FMS products.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2008 |
|---|---|---|---|
| Revenue | $0 | $15,737 | $0 |
| Net Loss | $(773,015) | $(2,515,440) | $(955,354) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.28) | $(0.35) |
| Cash and Cash Equivalents | $68,197 (as of Sep 30, 2009) Restricted Cash in Escrow: $163,333 |
||
| Total Assets | |||
| Total Liabilities | $2,689,878 (Current: $1,535,077; Long-term: $94,821; Equity-linked Liability: $1,059,980) | ||
| Shareholders' Deficit | $(2,280,343) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded its first revenue ($15,737) in the nine months ended September 30, 2009, compared to zero in the prior year period. This resulted from the first billable shipment of FMS units and cleaning kits in June 2009.
- Increased Losses: Net loss for the nine-month period increased significantly to $2.52 million from $955,000 in the prior year. This was driven by higher operating expenses and a $370,474 loss on the valuation of equity-linked financial instruments.
- Expense Growth:
- G&A Expenses: Increased to $1.39 million (9 months 2009) from $845,000 (9 months 2008), largely due to a $355,000 accrual for registration payment arrangements and increased consulting/legal fees.
- Operations Expense: Rose to $351,000 from $91,000, attributed to hiring an Executive VP of Operations and increased stock-based compensation.
- Sales & Marketing: Surged to $345,000 from $7,670 as the company ramped up sales activities post-FDA clearance.
- Accounting Changes: Adoption of EITF 07-5 in January 2009 reclassified certain warrants from equity to liability, creating a $1.06 million liability and impacting net loss through valuation adjustments.
Guidance, Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management expresses substantial doubt about the company's ability to continue as a going concern. Cash on hand ($68,197) is insufficient to fund operations beyond the fourth quarter of 2009 without additional financing.
- Capital Needs: The company requires approximately $3 million to $5 million in new equity to operate for the next 12 months. An investment banker (Newbridge Securities) was hired to raise this capital, with an interim closing of up to $500,000 targeted by January 31, 2010.
- Debt Obligations: The company has delinquent convertible debt totaling $170,000 and other overdue notes. While holders have verbally agreed to wait for new funding, they could legally demand payment, which would severely strain liquidity. A $170,000 note automatically converted to 620,095 shares upon the effective date of the registration statement (October 19, 2009).
- Legal Proceedings: A former officer filed a lawsuit in Minnesota state court in April 2009 alleging breach of contract and unpaid wages exceeding $100,000. The company denies the allegations and is defending the claim.
- Dilution Risk: Future equity financing will likely result in substantial dilution to existing shareholders. Additionally, the company is obligated to issue additional shares to investors if the registration statement is not effective within specific timeframes.
Investor Verification Checklist
- Capital Raise Status: Verify if the targeted $3-$5 million equity financing has been secured or if the interim $500,000 closing was achieved by the January 2010 deadline.
- Debt Resolution: Confirm the status of the $170,000 delinquent convertible debt and whether it has been fully converted to equity or if payment demands have been made.
- Legal Outcome: Check for updates on the lawsuit filed by the former officer regarding unpaid wages.
- Revenue Trajectory: Assess whether the initial $15,737 in revenue has scaled into recurring orders from medical facilities as anticipated.
- Equity Liability Volatility: Monitor the quarterly revaluation of the $1.06 million equity-linked liability, as changes in stock price or volatility assumptions will directly impact reported net loss.